T. Chan

发表

Abiraterone acetate in metastatic castration-resistant prostate cancer – the unanticipated real-world clinical experience

H. Sze, D. Lam, D. Poon, 2016, BMC Urology.

Hong Kong Urological Association–Hong Kong Society of Uro‐Oncology consensus statements on the management of advanced prostate cancer—2019 Updates

D. Poon, F. Cheung, H. So, 2021, Asia-Pacific journal of clinical oncology.

Consensus statements on the management of metastatic prostate cancer from the Hong Kong Urological Association and Hong Kong Society of Uro‐Oncology

D. Poon, F. Cheung, H. So, 2018, BJU international.

Prostate cancer management in the era of COVID‐19: Recommendations from the Hong Kong Urological Association and Hong Kong Society of Uro‐oncology

D. Poon, F. Cheung, H. So, 2021, Asia-Pacific journal of clinical oncology.

Ethnic Pharmacogenomic Differences in the Management of Asian Patients with Metastatic Prostate Cancer

H. Sze, D. Lam, Conrad Lee, 2022, Cancers.

Prevention of docetaxel‐associated febrile neutropenia with primary granulocyte colony‐stimulating factor in Chinese metastatic hormone‐sensitive and castration‐resistant prostate cancer patients

D. Poon, T. Chan, S. Siu, 2021, Asia-Pacific journal of clinical oncology.

Survival Outcomes, Prostate‐specific Antigen Response, and Tolerance in First and Later Lines of Enzalutamide Treatment for Metastatic Castration‐resistant Prostate Cancer: A Real‐World Experience in Hong Kong

Conrad Lee, K. C. Wong, D. Poon, 2018, Clinical genitourinary cancer.

Management of advanced prostate cancer in Hong Kong: Insights from an APCCC‐Derived survey

H. Sze, D. Poon, T. Chan, 2019, Asia-Pacific journal of clinical oncology.

Preliminary efficacy and tolerability of chemohormonal therapy in metastatic hormone‐naïve prostate cancer: The first real‐life experience in Asia

D. Lam, D. Poon, Kuen Chan, 2018, Asia-Pacific journal of clinical oncology.

Differences in clinical outcome between docetaxel and abiraterone acetate as the first-line treatment in chemo-naïve metastatic castration-resistant prostate cancer patients with or without the ineligible clinical factors of the COU-AA-302 study

H. Sze, D. Lam, D. Poon, 2017, Prostate international.

A Territory‐wide, Multicenter, Age‐ and Prostate‐specific Antigen‐matched Study Comparing Chemohormonal Therapy and Hormonal Therapy Alone in Chinese Men With Metastatic Hormone‐sensitive Prostate Cancer

D. Lam, C. Ng, D. Poon, 2019, Clinical genitourinary cancer.

Consensus statements on the management of clinically localized prostate cancer from the Hong Kong Urological Association and the Hong Kong Society of Uro‐Oncology

D. Poon, F. Cheung, H. So, 2019, BJU international.

Avelumab first-line maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Japanese subgroup analysis

S. Park, N. Tsuchiya, Jae-Lyun Lee, 2022, International Journal of Clinical Oncology.

Addressing the risk and management of cardiometabolic complications in prostate cancer patients on androgen deprivation therapy and androgen receptor axis-targeted therapy: consensus statements from the Hong Kong Urological Association and the Hong Kong Society of Uro-Oncology

T. Chan, P. Chiu, Marco T. Y. Chan, 2024, Frontiers in oncology.